{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16(3)"],"submitter":["Woldu SL"],"pubmed_abstract":["<h4>Introduction</h4>We aimed to determine whether anti-1-amino-3-<sup>18</sup>F-fluorocyclobutane-1-carboxylic acid (<sup>18</sup>F-fluciclovine) positron emission tomography/computed tomography (PET/CT) can accurately detect residual non-seminomatous germ cell tumor (NSGCT) prior to retroperitoneal lymph node dissection (RPLND). There is no reliable way to differentiate between fibrosis/necrosis, teratoma, and viable germ cell tumor in patients receiving post-chemotherapy RPLND. Functional imaging, including <sup>18</sup>F-fludeoxyglucose (18F-FDG) PET/CT, has been disappointing. Due to the need for better imaging modalities, our prospective, pilot study aims to investigate the accuracy of <sup>18</sup>F-fluciclovine PET/CT in detecting residual tumor prior to RPLND.<h4>Methods</h4>From "],"journal":["Canadian Urological Association journal = Journal de l'Association des urologues du Canada"],"pagination":["E167-E172"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8923889"],"repository":["biostudies-literature"],"pubmed_title":["Performance characteristics of <sup>18</sup>F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection."],"pmcid":["PMC8923889"],"pubmed_authors":["Wong D","Bagrodia A","Xi Y","Margulis V","Woldu SL","Baky F","Meng X","Subramaniam RM"],"additional_accession":[]},"is_claimable":false,"name":"Performance characteristics of <sup>18</sup>F-fluciclovine positron emission tomography/computed tomography prior to retroperitoneal lymph node dissection.","description":"<h4>Introduction</h4>We aimed to determine whether anti-1-amino-3-<sup>18</sup>F-fluorocyclobutane-1-carboxylic acid (<sup>18</sup>F-fluciclovine) positron emission tomography/computed tomography (PET/CT) can accurately detect residual non-seminomatous germ cell tumor (NSGCT) prior to retroperitoneal lymph node dissection (RPLND). There is no reliable way to differentiate between fibrosis/necrosis, teratoma, and viable germ cell tumor in patients receiving post-chemotherapy RPLND. Functional imaging, including <sup>18</sup>F-fludeoxyglucose (18F-FDG) PET/CT, has been disappointing. Due to the need for better imaging modalities, our prospective, pilot study aims to investigate the accuracy of <sup>18</sup>F-fluciclovine PET/CT in detecting residual tumor prior to RPLND.<h4>Methods</h4>From ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T12:45:06.387Z","creation":"2025-04-04T12:45:06.387Z"},"accession":"S-EPMC8923889","cross_references":{"pubmed":["35231393"],"doi":["10.5489/cuaj.7317"]}}